|Table of Contents|

Efficacy evaluation and influencing factors of autologous hematopoietic stem cell transplantation following chemotherapy in the treatment of lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 03
Page:
509-513
Research Field:
Publishing date:

Info

Title:
Efficacy evaluation and influencing factors of autologous hematopoietic stem cell transplantation following chemotherapy in the treatment of lymphoma
Author(s):
PINGCUO Zhuoga1; ZUO Xuying2; WANG Jianli1; HE Aili1; ZHANG Pengyu1
1.Department of Hematology;2.Department of Blood Transfusion,the Second Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710004,China.
Keywords:
lymphoma; high-dose chemotherapy; autologous hematopoietic stem cell transplantation; prognosis influencing factor
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2022.03.027
Abstract:
Objective:To explore the efficacy and influencing factors of autologous hematopoietic stem cell transplantation(auto-HSCT)following chemotherapy in the treatment of lymphoma.Methods:Retrospective analysis was made in lymphoma patients treated with high-dose chemotherapy(HDC)and sequential auto-HSCT in our department from Sep. 2015 to Dec. 2020，the efficacy and adverse reactions were evaluated.Results:40 patients, including 34 cases of non-Hodgkin lymphoma and 6 cases of Hodgkin lymphoma; There were 27 males and 13 females, with a median age of 44 (15-65) years.Except for 2 patients who died early after auto-HSCT,the remaining 38 patients had hematopoietic reconstruction.The median platelet engraftment time was 10(6~15)days,median neutrophil engraftment time was 9(7~14)days.25 patients(62.5%)had complete remission before transplantation,9 cases(22.5%)had partial remission,6 cases(15%)had no remission.The early transplantation related mortality(TRM)occurred in 2 cases(5%).The median follow-up time was 27(0.2~64)months.1 year and 3 years overall survival(OS)rates were 92.3% and 85.4%.1 year and 3 years progression-free survival(PFS)rates were 81.6% and 66.9%.Whether achieving complete remission（CR）before transplantation was major risk factor affecting the prognosis of lymphoma patients with auto-HSCT（P＜0.05），and an independent risk factor affecting PFS（P＜0.05）.Conclusion:HDC followed by auto-HSCT is a safe and effective treatment for lymphoma.Achieving CR before transplantation is beneficial for the therapeutic outcome.

References:

[1]王强力，黄海雯，金正明，等.自体和异基因造血干细胞移植治疗60例高危外周T细胞淋巴瘤患者的疗效比较［J］.中华血液学杂志，2016，37（11）：952-956. WANG QL,HUANG HW,JIN ZM,et al.Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas ［J］.Chinese Journal of Hematology,2016,37(11):952-956.
[2]ZAHID U,AKBAR F,AMARANENI A,et al.A review of autologous stem cell transplantation in lymphoma［J］.Curr Hematol Malig Rep,2017,12(3):217-226.
[3]孙艳，郭莉，胡欣,等.大剂量化疗联合自体造血干细胞移植治疗68例淋巴瘤临床疗效分析［J］.中华肿瘤防治杂志，2019，26（13）：963-968. SUN Y,GUO L,HU X,et al.Clinical analysis of high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation for treatment of lymphoma［J］.Chinese Journal of Cancer Prevention and Treatment,2019,26(13):963-968.
[4]DAMAJ G,CORNILLON J,BOUABDALLAH K,et al．Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma:a review［J］．Bone Marrow Transplant,2017,52(7):941-949.
[5]STIFF PJ,UNGER JM,COOK JR,et al.Autologous transplantation as consolidation for aggressive Non-Hodgkin's lymphoma［J］.N Engl J Med,2013,369(18):1681-1690.
[6]SWERDLOW SH,CAMPO E,PILERI SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］.Blood,2016,127(20):2375-2390.
[7]HAIOUN C,LEPAGE E,GISSELBRECHT C,et al.Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:final analysis of the prospective LNH87-2 protocol-a groupe d' Etude des lymphomes de l' Adulte study［J］.J Clin Oncol,2000,18(16):3025-3030.
[8]SUN YC,SHENG LX,ZHOU M,et al.Comparison of therapeutic efficacy and complications between autologous stem cell transplantation and chemotherapy for large B-cell lymphoma:a meta-analysis［J］.Int J Clin Exp Pathol,2018,11(2):472-480.
[9] 汪颖，吴德沛，吴小津，等.高剂量化疗和自体干细胞移植治疗T细胞淋巴瘤的疗效比较［J］.中华肿瘤杂志，2010，32(04):298-299,15. WANG Y,WU DP,WU XJ,et al.Comparison of the therapeutic effects of high-dose chemotherapy and autologous stem cell transplantation in T cell lymphoma ［J］.Chinese Journal of Oncology,2010,32(4):298-299,15.
[10]FREYTES CO,LOBERIZA FR,RIZZO JD.Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:a report of the International Bone Marrow Transplant Registry ［J］.Blood,2004,104(12):3797-3803.
[11]邹外一，童秀珍，许多荣，等.自体与异基因造血干细胞移植治疗侵袭性非霍奇金氏淋巴瘤疗效比较［J］.中山大学学报（医学科学版），2008，29（5）：620-623. ZOU WY,TONG XZ,XU DR,et al.Effect comparison between autologus and allogeneic hematopoietic stem cell transplantation for patients of aggressive non-Hodgkin's lymphoma［J］.Journal of Sun Yat-sen University(Medical Sciences),2008,29(5):620-623.
[12]JO JC,KANG BW,JANG G,et al.BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients:comparative analysis of efficacy and toxicity［J］.Ann Hematol,2008,87(1):43-48.
[13] 王清松，王凌云，王萍.恶性淋巴瘤患者自体造血干细胞移植治疗后的生存及预后因素分析［J］.实用癌症杂志，2020，35（5）：756-759. WANG QS,WANG LY,WANG P.Analysis of survival and prognosis factors in patients with malignant lymphoma after autologous hematopoietic stem cell transplantation［J］.The Practical Journal of Cancer,2020,35(5):756-759.
[14]刘心,周柰岑,张海涛,等.自体造血干细胞移植治疗恶性淋巴瘤15例临床分析［J］.现代肿瘤医学，2013，21(06)：1330-1332. LIU X,ZHOU MC,ZHANG HT,et al.Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation in 15 patients［J］.Modern Oncology,2013，21(06)：1330-1332.
[15]王莉，范磊，缪扣荣，等.自体造血干细胞移植治疗81例恶性淋巴瘤患者临床分析［J］.中华血液学杂志，2014，35(4)：328-331. WANG L,FAN L,MIAO KR,et al.Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation ［J］.Chinese Journal of Hematology,2014,35(4):328-331.
[16]GUI L,SHI YK,HE XH,et al.High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma:treatment outcome and prognostic factor analysis［J］.Int J Hematol,2014,99(1):69-78.
[17]SHI Y,LIU P,ZHOU S,et al.Comparison of CBV,BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma:Efficacy and toxicity［J］.Asia-Pacific Journal of Clinical Oncology,2017,13(5):e423-e429.
[18]ISIDORI A,CHRISTOFIDES A,VISANI G.Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma:alternatives to BEAM conditioning［J］.Leuk Lymphoma,2016,57(11):2499-2509.
[19]李越洋，刘素，田晨.淋巴瘤患者接受自体造血干细胞移植的预处理方案研究进展［J］.国际输血及血液学杂志，2019，42（6）：514-518. LI YY,LIU S,TIAN C.Reasearch progress of conditioning regimens for autologous hematopoietic stem cell transplantation in patients with lymphoma［J］.International Journal of Blood Transfusion and Hematology,2019,42(6):514-518.
[20]VISANI G,MALERBA L,STEFANI PM,et al.BeEAM(bendamustine,etoposide,cytarabine,melphalan)before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients［J］.Blood,2011,118(12):3419-3425.
[21]HUANG H,ZHANG L,JIANG Y,et al.Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation［J］.Annals of Hematology,2019,98(5):1259-1266.
[22]杨懿春，岑雪波，罗小华，等.CEAC 预处理后行自体造血干细胞移植对非霍奇金淋巴瘤患者的疗效评价［J］.第三军医大学学报，2019，41(23)：2272-2279. YANG YC,CEN XB,LUO XH,et al.Efficacy of CEAC regimen before autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma:analysis of 102 cases［J］.Journal of Third Military Medical University,2019,41(23):2272-2279.

Memo

Memo:
陕西省西安市科技计划项目［编号：2017114SF/YX008(10)］
Last Update: 2021-12-31